N Pardo
Overview
Explore the profile of N Pardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh S, Jighly A, Sehgal D, Burgueno J, Joukhadar R, Singh S, et al.
Nat Food
. 2023 Apr;
2(10):819-827.
PMID: 37117978
The effective utilization of natural variation has become essential in addressing the challenges that climate change and population growth pose to global food security. Currently adopted protracted approaches to introgress...
2.
Cedres S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, et al.
Clin Transl Oncol
. 2020 Jan;
22(8):1390-1398.
PMID: 31916017
Background: Promising results have been reported with immune checkpoint inhibitors (ICI) in a small proportion of MPM patients. MMR deficiency (dMMR) has been well described in several malignancies and was...
3.
Remon J, Pardo N, Martinez-Marti A, Cedres S, Navarro A, Martinez de Castro A, et al.
Lung Cancer
. 2018 Feb;
117:80.
PMID: 29398170
No abstract available.
4.
Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedres S, et al.
Ann Oncol
. 2017 Sep;
28(10):2451-2457.
PMID: 28961841
Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. Different...
5.
Remon J, Pardo N, Martinez-Marti A, Cedres S, Navarro A, Martinez de Castro A, et al.
Lung Cancer
. 2017 Mar;
106:70-75.
PMID: 28285697
Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with...
6.
Santin S, Fraga G, Ruiz P, Pardo N, Torrent M, Marti T, et al.
Clin Nephrol
. 2011 Sep;
76(3):244-8.
PMID: 21888862
Wilms' tumor suppressor gene (WT1) encodes a transcription factor required for normal development of the genitourinary system. Germline WT1 mutations have been described in a wide spectrum of pathological conditions,...
7.
De las Marinas D, Cojocariu Z, Escudero R, Pardo N, Sanz M
J Investig Allergol Clin Immunol
. 2007 Aug;
17(4):283-4.
PMID: 17694709
No abstract available.
8.
Verdeguer A, Munoz A, Canete A, Pardo N, Martinez A, Donat J, et al.
Pediatr Hematol Oncol
. 2004 Nov;
21(6):495-504.
PMID: 15552813
The authors retrospectively analyzed the long-term outcome of 67 patients over 1 year of age at diagnosis with high-risk neuroblastoma (stage 4 or stage 3 with N-myc amplification) who were...
9.
Munoz A, Maldonado M, Pardo N, Fernandez J, Vela E, Cubells J
Pediatr Blood Cancer
. 2004 Jul;
43(2):152-5.
PMID: 15236282
No abstract available.
10.
Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernandez J, et al.
Bone Marrow Transplant
. 2000 Feb;
25(1):31-4.
PMID: 10654011
This study evaluates the outcome of myeloablative chemo-radiotherapy and autologous stem cell transplantation (ASCT) in children with Hodgkin's disease (HD). Twenty children aged 5 to 18 years (median 10.8 years)...